The drug, a non-insulin treatment, is a glucagon-like peptide receptor protein treatment. It is the first GLP treatment that doesn’t need to be injected.
The drug works by slowing digestion, preventing the liver from producing too much sugar and stimulating the pancreas produce more insulin.
“Patients want effective treatment options for diabetes that are as minimally intrusive on their lives as possible, and the FDA welcomes the advancement of new therapeutic options that can make it easier for patients to control their condition,” said Lisa Yanoff, MD, acting director of the FDA’s division of metabolism and endocrinology products.
More articles on pharmacy:
Carcinogen concerns prompt Sandoz to halt global distribution of heartburn drug
DEA raids some West Coast Kaiser Permanente pharmacies
California biotech files for bankruptcy
